To Reshore Generic Drugs, Use Sugar’s Sweet Model
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
ICYMI: CPA Economist Andrew Rechenberg Stars at Hearing on Fixing America’s Broken Drug Supply Chain
The hearing continued the committee’s efforts to examine and reduce America’s severely dangerous over-dependence on foreign-manufactured generic drugs and address vulnerabilities in the nation’s pharmaceutical supply chain.
CPA Calls on Trump Administration to Take Strong, Decisive Action to Decouple from China and Strengthen U.S. Industrial Capacity
The era of global dependency on the CCP is over. For decades, Wall Street, multinational corporations, and globalist institutions helped finance China’s rise at the direct expense of American workers, manufacturers, and national security.
CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
New CPA Economic Report on ‘The New Biotech Cold War’
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production
The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.
China Now Producing Dozens of Drugs Below Market Price – Dumping Them Globally is Next Move
As proof that no company can match China on price, Chinese producers of active pharmaceutical ingredients (APIs) and the key starting materials (KSMs) used to make them are slashing prices by up to 50%. Not even low-cost India – one of the largest importers of Chinese KSMs – can compete at those levels.
New CPA Report Shows Generic Drug Tariffs Will Not Raise Prices for Patients
The findings refute claims by the pharmaceutical lobby that tariffs would harm consumers, and instead underscore the urgent need for strong trade measures to reshore U.S. production of essential medicines.
The Price Impact of Generic Drug Tariffs: Why Patients Do Not Bear the Cost
America is dangerously reliant on high-risk foreign suppliers for essential generic drugs, especially APIs concentrated in China and India. That over-reliance has already triggered preventable crises, such as nationwide chemotherapy shortages when a single overseas plant shut down.
CPA: EU Must Reject Aurobindo’s $5.5 Billion Zentiva Takeover
Aurobindo Pharma’s proposed $5.5 billion acquisition of Prague-based Zentiva poses an unacceptable risk to Europe’s and America’s pharmaceutical security. CPA is calling on the European Union (EU), including Czech authorities and European Commission competition regulators, to reject the transaction.
